小児糖尿病治療の市場規模、シェア、動向分析レポート：タイプ別、治療法別、投与経路別、流通経路別、地域別、セグメント別予測、2024年～2030年

小児糖尿病治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の小児糖尿病治療市場規模は2030年までに221億4,000万米ドルに達し、2024年から2030年までのCAGRは13.9%で成長すると予測されています。

この市場を牽引しているのは、主に小児の糖尿病有病率の上昇と、早期診断と効果的な管理への注目の高まりです。国際糖尿病連合（IDF）は、2022年には世界で875万人の1型糖尿病（T1D）患者のうち、20歳未満は152万人に過ぎないと推定しています。この急増は、遺伝的素因、環境要因、生活パターンの変化によるところが大きいです。

糖尿病管理における技術的進歩は、市場成長にプラスの影響を与えると予想されます。持続グルコースモニター（CGM）、インスリンポンプ、人工膵臓システムなどの技術革新は、より良いグルコースコントロールを可能にし、合併症のリスクを低減します。例えば、米国FDAは2023年6月、10歳以上の2型糖尿病（T2D）の小児に、食事療法と運動療法の補助として血糖コントロールを改善する目的で、シンジャルディ（メトホルミン塩酸塩とエンパグリフロジンの配合剤）とジャーディアンス（エンパグリフロジン）を承認しました。今回の承認により、小児の2型糖尿病患者に対する治療選択肢が大幅に拡大され、臨床現場での薬剤の幅広い導入が促進されることが期待されます。この承認は、若年患者に対する効果的な治療法へのアクセスを拡大し、疾患管理の改善と長期的な健康転帰の改善につながる重要な一歩となります。

さらに、小児の疾患に対する認識の高まりと早期診断により、インスリン治療薬、ビグアナイド薬、GLP-1受容体作動薬、SGLT2阻害薬など、さまざまな治療選択肢の採用が増加しています。また、小児の糖尿病治療へのアクセスを改善することを目的とした、政府の支援的な取り組みや政策も市場を牽引しています。世界の小児人口は増加の一途をたどっており、糖尿病の有病率も増加していることから、糖尿病治療に対する需要は予測期間中に大きく伸びると予想されます。

小児糖尿病治療市場レポートハイライト

• 1型セグメントは2023年に79.32%の最大収益シェアを占めました。これは、1型疾患の罹患率と有病率の増加、および世界の新規治療に対する需要の高さに起因しています。
• 治療法では、インスリンセグメントが2023年に35.88%の最大シェアを占めています。これは、小児患者に害を与えることなく安全かつ効果的にインスリンを投与するための新しいデリバリーシステムの開発と商業化に起因しています。
• 投与経路では、非経口部門が2023年の市場で62.50%の最大シェアを占めています。これは、小児糖尿病患者の治療において、新しい皮下注射薬や静脈注射薬が承認されつつあることに起因しています。
• 流通経路では、小売薬局セグメントが2023年の市場で47.49%の最大シェアを占めています。これは、糖尿病治療のための小児患者の処方箋を補充するための薬剤の容易なアクセス性と可用性などの利点に起因することができます。
• 北米は2023年に41.49%のシェアを占め、市場を独占しました。これは、高度なヘルスケアインフラ、小児の糖尿病有病率の増加、臨床試験と治療のための有利な規制と償還などの要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 小児糖尿病治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 小児糖尿病治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 小児糖尿病治療薬市場：タイプの推定・動向分析

• 世界の小児糖尿病治療薬市場：タイプダッシュボード
• 世界の小児糖尿病治療薬市場：タイプ変動分析
• タイプ別、収益
• タイプ1
• タイプ2

第5章 小児糖尿病治療市場：治療法の推定・動向分析

• 世界の小児糖尿病治療市場：治療法ダッシュボード
• 世界の小児糖尿病治療市場：治療法変動分析
• 治療法別、収益
• インスリン
• GLP-1受容体作動薬
• ビグアナイド
• SGLT2阻害剤
• その他

第6章 小児糖尿病治療薬市場：投与経路の推定・動向分析

• 世界の小児糖尿病治療薬市場：投与経路ダッシュボード
• 世界の小児糖尿病治療薬市場：投与経路の変動分析
• 投与経路別、収益
• 経口
• 非経口
• その他

第7章 小児糖尿病治療薬市場：流通経路の推定・動向分析

• 世界の小児糖尿病治療薬市場：流通経路ダッシュボード
• 世界の小児糖尿病治療薬市場：流通経路変動分析
• 流通経路別、収益
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 小児糖尿病治療薬市場：製品、用途、最終用途、地域別推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company market share analysis, 2023
  • Boehringer Ingelheim International GmbH.
  • Eli Lilly and Company
  • Sanofi
  • Vertex Pharmaceuticals Incorporated
  • Novo Nordisk A/S
  • AstraZeneca.
  • MannKind Corporation
  • Xeris Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
• Table 3 North America pediatric diabetes therapeutic market, by Type, 2018 - 2030 (USD Million)
• Table 4 North America pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 5 North America pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 6 North America pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 U.S. pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 8 U.S. pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 9 U.S. pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 10 U.S. pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Canada pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 12 Canada pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 13 Canada pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 Canada pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Mexico pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 16 Mexico pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 17 Mexico pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Mexico pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 Europe pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
• Table 20 Europe pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 21 Europe pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 22 Europe pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 23 Europe pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Germany pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 25 Germany pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 26 Germany pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 Germany pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 UK pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 29 UK pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 30 UK pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 UK pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 France pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 33 France pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 34 France pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 35 France pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Italy pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 37 Italy pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 38 Italy pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 Italy pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Spain pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 41 Spain pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 42 Spain pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Spain pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Denmark pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 45 Denmark pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 46 Denmark pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 47 Denmark pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Sweden pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 49 Sweden pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 50 Sweden pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 51 Norway pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 52 Norway pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 53 Norway pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 54 Norway pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 60 China pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 61 China pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 62 China pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 63 China pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64 Japan pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 65 Japan pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 66 Japan pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 67 Japan pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 68 India pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 69 India pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 70 India pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 71 India pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 72 South Korea pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 73 South Korea pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 74 South Korea pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 75 South Korea pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 76 Australia pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 77 Australia pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 78 Australia pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 79 Australia pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80 Thailand pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 81 Thailand pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 82 Thailand pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 83 Thailand pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84 Latin America pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
• Table 85 Latin America pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 86 Latin America pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 87 Latin America pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 88 Latin America pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 89 Brazil pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 90 Brazil pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 91 Brazil pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 92 Brazil pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93 Argentina pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 94 Argentina pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 95 Argentina pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 96 Argentina pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 97 MEA pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
• Table 98 MEA pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 99 MEA pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 100 MEA pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 101 MEA pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 102 South Africa pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 103 South Africa pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 104 South Africa pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 105 South Africa pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 110 UAE pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 111 UAE pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 112 UAE pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 113 UAE pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
• Table 114 Kuwait pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
• Table 115 Kuwait pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
• Table 116 Kuwait pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
• Table 117 Kuwait pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Pediatric diabetes therapeutic market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Pediatric diabetes therapeutic market snapshot
• Fig. 10 Pediatric diabetes therapeutic market driver impact
• Fig. 11 Pediatric diabetes therapeutic market restraint impact
• Fig. 12 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Value chain analysis
• Fig. 15 Pediatric diabetes therapeutic market: Type Outlook and key takeaways
• Fig. 16 Pediatric diabetes therapeutic market: Type movement analysis
• Fig. 17 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Pediatric diabetes therapeutic market: Treatment outlook and key takeaways
• Fig. 20 Pediatric diabetes therapeutic market: Treatment movement analysis
• Fig. 21 Insulin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 GLP-1 Receptor Agonists market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Biguanide market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 SGLT2 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Pediatric diabetes therapeutic market: Route of administration outlook and key takeaways
• Fig. 27 Pediatric diabetes therapeutic market: Route of administration movement analysis
• Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Pediatric diabetes therapeutic market: Distribution channel outlook and key takeaways
• Fig. 32 Pediatric diabetes therapeutic market: Distribution channel movement analysis
• Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Global pediatric diabetes therapeutic market: Regional movement analysis
• Fig. 37 Global pediatric diabetes therapeutic market: Regional outlook and key takeaways
• Fig. 38 Global pediatric diabetes therapeutic market share and leading players
• Fig. 39 North America, by country
• Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 U.S. key country dynamics
• Fig. 42 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Canada key country dynamics
• Fig. 44 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Mexico key country dynamics
• Fig. 46 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 UK key country dynamics
• Fig. 49 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Germany key country dynamics
• Fig. 51 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 France key country dynamics
• Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Italy key country dynamics
• Fig. 55 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Spain key country dynamics
• Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Denmark key country dynamics
• Fig. 59 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Sweden key country dynamics
• Fig. 61 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Norway key country dynamics
• Fig. 63 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 China key country dynamics
• Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Japan key country dynamics
• Fig. 68 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 India key country dynamics
• Fig. 70 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Thailand key country dynamics
• Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 South Korea key country dynamics
• Fig. 74 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Australia key country dynamics
• Fig. 76 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Brazil key country dynamics
• Fig. 79 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Argentina key country dynamics
• Fig. 81 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 South Africa key country dynamics
• Fig. 84 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Saudi Arabia key country dynamics
• Fig. 86 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 UAE key country dynamics
• Fig. 88 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Kuwait key country dynamics
• Fig. 90 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Market share of key market players- pediatric diabetes therapeutic market

Pediatric Diabetes Therapeutic Market Growth & Trends:

The global pediatric diabetes therapeutic market size is anticipated to reach USD 22.14 billion by 2030, growing at a CAGR of 13.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the rising prevalence of diabetes among children and the increasing focus on early diagnosis and effective management. The International Diabetes Federation (IDF) estimates that in 2022, out of the 8.75 million people living with type 1 diabetes (T1D) worldwide, only 1.52 million were under the age of 20. This surge is largely due to genetic predisposition, environmental factors, and changes in lifestyle patterns.

Technological advancements in diabetes management are anticipated to positively impact market growth. Innovations such as continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas systems enable better glucose control, reducing the risk of complications. For example, in June 2023, the U.S. FDA approved Synjardy (a combination of metformin hydrochloride and empagliflozin) and Jardiance (empagliflozin) for use in children aged 10 and older with type 2 diabetic (T2D), as an adjunct to diet and exercise for better blood sugar control. This approval is expected to significantly enhance treatment options for pediatric with T2D, encouraging broader adoption of these medications in clinical practice. It marks a critical step in expanding access to effective therapies for younger patients, leading to improved disease management and better long-term health outcomes.

Furthermore, the growing awareness and early diagnosis of disease in children have led to an increase in the adoption of various treatment options, including insulin therapies, biguanides, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is also driven by supportive government initiatives and policies aimed at improving access to diabetic care for children. As the global children population continues to rise, along with the increasing prevalence of diabetes, the demand for diabetic treatment is expected to grow significantly during the forecast period.

Pediatric Diabetes Therapeutic Market Report Highlights:

• The type 1 segment held the largest revenue share of 79.32% in 2023. This can be attributed to the increasing incidence and prevalence of type 1 disease and high demand for new therapy treatment across worldwide.
• In treatment, the insulin segment is held the largest share of 35.88% of the market in 2023. This can be attributed to the development and commercialization of novel delivery systems to deliver insulin safely and effectively to children's patients without harm.
• In route of administration, the parenteral segment is held the largest share of 62.50% of the market in 2023. This can be attributed to the growing approval of new subcutaneous and intravenous medicine for treatment of pediatric diabetes patient.
• In distribution channel, the retail pharmacies segment is held the largest share of 47.49% of the market in 2023. This can be attributed to its advantages such as easy accessibility and availability of medication to refill prescriptions of pediatric patients for diabetes treatment.
• North America dominated the market in 2023 with a share of 41.49%, owing to factors such as advanced healthcare infrastructure, increasing prevalence of diabetic in children, and favorable regulatory and reimbursement for clinical trial and treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and treatment outlook
  • 2.2.2. Route of administration and distribution channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pediatric diabetes therapeutic market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of diabetic diseases in children
    • 3.2.1.2. Rising awareness about diabetes
    • 3.2.1.3. Advancement in treatment methodologies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Stringent regulations pertaining to drug approval
• 3.3. Pediatric Diabetes Therapeutic Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Pediatric diabetes therapeutic market: Type Estimates & Trend Analysis

• 4.1. Global Pediatric Diabetes Therapeutic Market: Type Dashboard
• 4.2. Global Pediatric Diabetes Therapeutic Market: Type Movement Analysis
• 4.3. Global Pediatric Diabetes Therapeutic Market By Type, Revenue (USD Million)
• 4.4. Type 1
  • 4.4.1. Type 1 market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Type 2
  • 4.5.1. Type 2 market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pediatric diabetes therapeutic market: Treatment Estimates & Trend Analysis

• 5.1. Global Pediatric Diabetes Therapeutic Market: Treatment Dashboard
• 5.2. Global Pediatric Diabetes Therapeutic Market: Treatment Movement Analysis
• 5.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
• 5.4. Insulin
  • 5.4.1. Insulin market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. GLP-1 Receptor Agonists
  • 5.5.1. GLP-1 Receptor Agonists market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Biguanide
  • 5.6.1. Biguanide market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. SGLT2 Inhibitors
• 5.8. SGLT2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pediatric diabetes therapeutic market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Pediatric Diabetes Therapeutic Market: Route of Administration Dashboard
• 6.2. Global Pediatric Diabetes Therapeutic Market: Route of Administration Movement Analysis
• 6.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 6.4. Oral
  • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Parenteral
  • 6.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pediatric diabetes therapeutic market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Dashboard
• 7.2. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Movement Analysis
• 7.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pediatric diabetes therapeutic market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2023
  • 9.3.2. Boehringer Ingelheim International GmbH.
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Eli Lilly and Company
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Sanofi
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Vertex Pharmaceuticals Incorporated
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Novo Nordisk A/S
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. AstraZeneca.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. MannKind Corporation
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Xeris Pharmaceuticals
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Amphastar Pharmaceuticals, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives